Hypophosphatemia in people with HIV: no benefit when switching from tenofovir disoproxil fumarate to tenfovir alafenamide.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
pubmed:
9
4
2021
medline:
7
8
2021
entrez:
8
4
2021
Statut:
ppublish
Résumé
Treatment with tenofovir disoproxil fumarate (TDF) has been associated with hypophosphatemia mainly because of injury of the renal proximal tubulus. Studies on the impact of tenfovir alafenamide (TAF) on phosphate homeostasis in people with HIV (PWH) are limited. Prompted by a patient with phosphate wasting under tenofovir but no other evidence for tubular dysfunction, a retrospective cohort analysis with 102 PWH revealed that hypophosphatemia remained largely unchanged after switching from TDF to TAF.
Identifiants
pubmed: 33831912
doi: 10.1097/QAD.0000000000002905
pii: 00002030-202107150-00024
doi:
Substances chimiques
Anti-HIV Agents
0
Fumarates
0
Tenofovir
99YXE507IL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1516-1518Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Buchacz K, Brooks JT, Tong T, Moorman AC, Baker RK, Holmberg SD, et al. Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy . HIV Med 2006; 7:451–456.
Badiou S, De Boever CM, Terrier N, Baillat V, Cristol JP, Reynes J. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? . J Infect 2006; 52:335–338.
McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers . Clin Infect Dis 2010; 51:937–946.
Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, Post FA. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase . AIDS 2010; 24:1923–1928.
Masiá M, Padilla S, Robledano C, López N, Ramos JM, Gutiérrez F. Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir . AIDS Res Hum Retroviruses 2012; 28:242–246.
Fux CA, Christen A, Zgraggen S, Mohaupt MG, Furrer H. Effect of tenofovir on renal glomerular and tubular function . AIDS 2007; 21:1483–1485.
Kinai E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels . AIDS 2005; 19:2031–2033.
Hamzah L, Williams D, Bailey AC, Jones R, Ibrahim F, Musso CG, et al. Fanconi-Tenofovir Alafenamide trial team. Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial . HIV Med 2020; 21:198–203.
Seo JW, Kim K, Jun K Il, Kang CK, Moon SM, Song KH, et al. Recovery of tenofovir-induced nephrotoxicity following switch from tenofovir disoproxil fumarate to tenofovir alafenamide in human immunodeficiency virus-positive patients . Infect Chemother 2020; 52:381–388.
Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. GS-US-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection . J Hepatol 2018; 68:672–681.
Fong T-L, Lee BT, Tien A, Chang M, Lim C, Ahn A, Bae HS. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide . J Viral Hepat 2019; 26:561–567.